Risk-based Monitoring Software Key Players Influencing the Market
The report provides key statistics on the market status of the leading Risk-based Monitoring (RBM) Software market players and offers key trends and opportunities in the market.
The report provides key statistics on the market status of the leading Risk-based Monitoring (RBM) Software market players and offers key trends and opportunities in the market.
MyRBQM® Portal's new Machine Learning predictive analytics model is far less sensitive to noise, it better generalizes data, and provides narrower CIs in long time series. Singular Spectrum Analysis is particularly valuable for long time series, as mostly observed in clinical trials.
We've created this "ask the experts" Q&A to provide clear responses to the questions that were most often asked by the forum's participants.
Frontiers Health Ecosystem Companies Fighting Back the COVID-19 Outbreak As the COVID-19 outbreak continues, it has become even more challenging for patients to seek in- person medical care and for healthcare providers (HCP) to guarantee community health services for people who may have symptoms [...]
Cyntegrity developed a special COVID-19 RACT that guides those involved in clinical trials on specific risks which may arise as a result of COVID-19, and how they can mitigate them. This special RACT is part of the COVID-19 rapid deployment pack for ad-hoc centralized monitoring.
We can help establish near real-time centralized monitoring, enable the use of "ad-hoc crisis management" Key Risk Indicators (KRIs), and mitigate patient safety and study quality risks.
This week Applied Clinical Trials published an interesting case study of the risk-based quality management learning curve. The provision of a set of training modules helped Merz Pharma to initiate a smooth RBQM rollout.
Adaptive and intelligent Risk Based Quality Management (RBQM) is a powerful strategy for rare disease research. One of the main benefits is that RBQM allows for patient-centric trial design that is uniquely tailored to the specific rare disease.
The need for a controlled research environment adds another risk dimension to the Phase 1 study design. The new Healthy Volunteers - Phase 1 RACT serves as a helpful source to ensure maximum subject safety and a reliable outcome.
As change can be a significant source of risk, RBQM or risk-based monitoring (RBM) implementation programs should include a roadmap and change management plan for initiating a process of continuous improvement.